Precision BioLogic Acquires Affinity Biologicals
HALIFAX, Nov. 1, 2018 /PRNewswire/ - Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the completed acquisition of Affinity Biologicals Inc., a primary manufacturer of reagents and kits used in hemostasis and thrombosis research and diagnostics.
"This acquisition marks an important step in the development of our company and execution of our strategic plan," says Paul Empey, President & CEO of Precision BioLogic. "The two organizations serve a similar market with complementary product lines, which will allow us to better serve existing customers and develop new products for research and diagnostics."
Affinity President Hugh Hoogendoorn agrees. "It's a logical fit," he says. "Affinity and Precision BioLogic share many of the same guiding principles, including a commitment to quality products and service. The resulting synergy will create exciting opportunities for us and our customers."
The two organizations will continue to focus on their customers and regular operations while developing longer term strategic plans under the Precision BioLogic umbrella.
About Affinity Biologicals
Affinity Biologicals Inc. was founded in 1987 by Hugh and Patricia Hoogendoorn. With a strong background in hemostasis research and a focus on reagent and assay development, Affinity has become a primary manufacturer of more than 300 reagents and kits used in hemostasis and thrombosis research and diagnostics. Affinity's product line includes: an extensive line of coagulation related antibodies, conjugates, matched-pair antibody sets for immunoassay of human and animal analytes, the VisuLize(TM) line of complete ELISA kits, and a full line of human plasma products including VisuDep(TM) Immune-Depleted Factor-Deficient Plasmas, VisuCal(TM) Calibrator Plasma and VisuCon(TM) Control Plasmas. Services include protein purification, antibody production, assay development, custom manufacturing including custom lyophilization and proficiency testing materials. All products are manufactured in its Ancaster, ON (Canada) facility, products are sold direct in North America and worldwide through a network of branded and private-label distributors. For more information, visit www.affinitybiologicals.com.
About Precision BioLogic
Precision BioLogic Inc. is a privately-held company that develops, manufactures and markets the cryocheck(TM) line of frozen products used by medical professionals and researchers around the globe to diagnose coagulation disorders. Precision BioLogic also has several active initiatives with pharmaceutical partners who seek to ensure that the diagnostic implications for their novel therapeutic agents have been well characterized. For more information, visit www.precisionbiologic.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-biologic-acquires-affinity-biologicals-300741421.html
SOURCE Precision BioLogic
